Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature Medicine (5)
Nature Communications (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (4)
Amendments and Corrections (2)

Subject Check one or more subjects to show results from those subjects only.

Diseases
Immunology
Medical research
Microbiology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–6 of 6 results

Advanced filters: Author: Emma Plested Clear advanced filters

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Two doses of the coronavirus disease 2019 vaccine ChAdOx1 nCoV-19 boost antibody responses and functions in phase 1/2 trial participants.

Jordan R. Barrett
Sandra Belij-Rammerstorfer
Dalila Zizi
Research17 Dec 2020
Nature Medicine

Volume: 27, P: 279-288
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Jordan R. Barrett
Sandra Belij-Rammerstorfer
Dalila Zizi
Amendments and Corrections06 May 2021
Nature Medicine

Volume: 27, P: 1113
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Katie J. Ewer
Jordan R. Barrett
Elizabeth Stafford
Amendments and Corrections21 May 2021
Nature Medicine

Volume: 27, P: 1116
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine ChAdOx1 nCoV-19 are identified as correlates of protection against symptomatic infection.

Shuo Feng
Daniel J. Phillips
Christopher J. Williams
ResearchOpen Access29 Sept 2021
Nature Medicine

Volume: 27, P: 2032-2040
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Emerging variants of SARS-CoV-2 raise concerns about vaccine efficiency. Here, the authors present a post-hoc analysis for the ChAdOx1 nCoV-19 (AZD1222) vaccine trial in Brazil and provide efficacy against symptomatic COVID-19 caused by the Zeta (P.2) and other variants.

Sue Ann Costa Clemens
Pedro M. Folegatti
Rafael Zimmer
ResearchOpen Access06 Oct 2021
Nature Communications

Volume: 12, P: 1-10
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

A single dose of the ChAdOx1 nCoV-19 vaccine elicits antibodies and cytokine-producing T cells that might help control or prevent SARS-CoV-2 infection.

Katie J. Ewer
Jordan R. Barrett
Elizabeth Stafford
Research17 Dec 2020
Nature Medicine

Volume: 27, P: 270-278